Maravai LifeSciences (MRVI) Downgraded by Zacks Investment Research to Hold

Maravai LifeSciences stock has undergone multiple analysts rating changes in the recent past.  Maravai LifeSciences Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Maravai LifeSciences traded down -$0.67 on Tuesday, reaching $38.18. 0 shares of the stock traded hands, compared to its average volume of 2427742. Shares of Maravai LifeSciences were trading at $38.18 on Tuesday. The firm’s 50 day moving average is $51.44 and its 200 day moving average is $40.14.Maravai LifeSciences has a 12 month low of $36.89 and a 12 month high of $63.55. While on yearly highs and lows, Maravai LifeSciences’s today has traded high as $39.60 and has touched $36.89 on the downward trend. See More Analyst Rating at: RATING

Maravai LifeSciences Earnings and What to expect: 

Maravai LifeSciences last issued its earnings results on August 10th, 2021. The reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $217.80 million for the quarter, compared to the consensus estimate of $195.49 million. Its revenue was up 364.4% on a year-over-year basis. Maravai LifeSciences has generated $1.70 earnings per share over the last year and currently has a price-to-earnings ratio of 22.5. Earnings for Maravai LifeSciences are expected to decrease by -3.62% in the coming year, from $1.38 to $1.33 per share. Maravai LifeSciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

Earnings for Maravai LifeSciences are expected to decrease by -3.62% in the coming year, from $1.38 to $1.33 per share. The P/E ratio of Maravai LifeSciences is 22.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.78. The P/E ratio of Maravai LifeSciences is 22.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 32.65. Maravai LifeSciences has a P/B Ratio of 63.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Maravai LifeSciences (MRVI) Moving Average Technical Analysis

5 day Moving Average is $40.65 And 5 day price change is -$4.74 (-11.04%)  with average volume for 5 day average is 1,553,300. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $45.42 and 20 day price change is -$8.53 (-18.26%) and average 20 day moving volume is 2,080,545. 50 day moving average is $51.44  and 50 day price change is -$6.14 ( -13.85%)  and with average volume for 50 days is : 1,920,484. 200 day moving average is $40.14  and 200 day price change is $8.47 (28.51%)  and with average volume for 200 days is : 1,443,624.

Other owners latest trading in Maravai LifeSciences :

  • On 10/8/2021 shares held by Carnegie Capital Asset Management LLC were 12,580 which equates to market value of $0.62M and appx 0.00% owners of Maravai LifeSciences
  • On 9/17/2021 shares held by Virtu Financial LLC were 9,631 which equates to market value of $0.40M and appx 0.00% owners of Maravai LifeSciences
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 29,656 which equates to market value of $1.24M and appx 0.00% owners of Maravai LifeSciences
  • In total Institutional ownership equates to Institutional Ownership Percentage: 44.13% for Maravai LifeSciences

See More Analyst Rating at: RATING